Kymera Therapeutics Past Earnings Performance
Past criteria checks 0/6
Kymera Therapeutics's earnings have been declining at an average annual rate of -29.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 5.4% per year.
Key information
-29.9%
Earnings growth rate
64.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 5.4% |
Return on equity | -23.0% |
Net Margin | -178.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Jul 04Revenue & Expenses Breakdown
How Kymera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 89 | -158 | 60 | 0 |
31 Mar 24 | 79 | -155 | 57 | 0 |
31 Dec 23 | 79 | -147 | 55 | 0 |
30 Sep 23 | 47 | -167 | 52 | 0 |
30 Jun 23 | 52 | -158 | 49 | 0 |
31 Mar 23 | 47 | -159 | 46 | 0 |
31 Dec 22 | 47 | -155 | 44 | 0 |
30 Sep 22 | 46 | -154 | 44 | 0 |
30 Jun 22 | 57 | -139 | 44 | 0 |
31 Mar 22 | 64 | -124 | 41 | 0 |
31 Dec 21 | 73 | -100 | 36 | 0 |
30 Sep 21 | 70 | -79 | 30 | 0 |
30 Jun 21 | 65 | -58 | 26 | 0 |
31 Mar 21 | 49 | -48 | 22 | 0 |
31 Dec 20 | 34 | -55 | 18 | 0 |
30 Sep 20 | 23 | -53 | 16 | 0 |
30 Jun 20 | 9 | -57 | 10 | 0 |
31 Mar 20 | 6 | -52 | 9 | 0 |
31 Dec 19 | 3 | -41 | 8 | 0 |
Quality Earnings: KYMR is currently unprofitable.
Growing Profit Margin: KYMR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KYMR is unprofitable, and losses have increased over the past 5 years at a rate of 29.9% per year.
Accelerating Growth: Unable to compare KYMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KYMR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: KYMR has a negative Return on Equity (-23.05%), as it is currently unprofitable.